Interferon-α therapy has proved effective for up to 40% of patients with adult-acquired chronic hepatitis B virus (HBV) infection and for 20–25% of those with chronic hepatitis C virus (HCV) infection. Nucleoside analogues, such as lamivudine and famciclovir, are showing promise as antiviral agents for chronic HBV and the combination of interferon-α and ribavirin is proving to be successful therapy for 40–50% of patients with chronic HCV. In this article we review current therapy and discuss future strategies of the therapy of chronic viral hepatitis.
AgnelloVChungRT & KaplanLM (1992) A role for hepatitis C virus infection in type II cryoglobulinemia. New England Journal of Medicine327: 1490–1495.
2.
AyeTTBartholomeuszAShawTBowdenSBreschkinA & McMillanJ (1997) Hepatitis B virus polymerase mutations during antiviral therapy in a patient following transplantation. Journal of Hepatology26: 1148–1153.
3.
BartenschlagerR (1997) Molecular targets in inhibition of hepatitis C virus replication. Antiviral Chemistry & Chemotherapy8: 281–301.
4.
BartholomewMMJansenRWJeffersLJReddyKRJohnsonLCBunzendahlHCondreayLTzakisAGSchiffER & BrownN (1997) Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet349: 20–22.
5.
BassendineMFChadwickRG & SalmeronJ (1981) Adenine arabinoside therapy in HBsAg-positive chronic liver disease: A controlled study. Gastroenterology80: 1016–1021.
6.
BellobuonoAMondazziLTempiniSGBCassaraLLombinoMSiliniEBonoF, & IdeoG (1994) Efficacy of different regimens of alpha interferon in chronic hepatitis C and relationship between response and HCV genotype. Journal of Hepatology (Suppl.) 21: 35.
7.
BennettWGInoueYBeckJRWongJBPaukerSG & DavisGL (1997) Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Annals of Internal Medicine127: 855–865.
8.
BisollonTPalazzoUDucerfCChevallierMElliottM & BaulieuxJ (1997) Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology26: 500–504.
9.
BloomerJCanRShermanMIngrahamP & DeHertogD (1997) A preliminary study of lobucavir for chronic hepatitis B. Hepatology25: A1199.
10.
BodenheimerHCLindsayKLDavisGLLewisJHThungSN & SeeffLB (1997) Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology26: 473–477.
11.
BodsworthNJCooperDA & DonovanB (1991) The influence of human immunodeficiency virus type 1 on the development of the hepatitis B virus carrier state. Journal of Infectious Diseases163: 1138–1140.
12.
BoothJCLFosterGRKumarUGalassiniRGoldinRDBrownJL & ThomasHC (1995) Chronic hepatitis C virus infection: Predictive value of genotype and level of viraemia on disease progression and response to interferon alpha. Gut36: 427–432.
13.
BrillantiSGarsonJFoliMWhitbyKDeavilleRMasciCMiglioliM & BarbaraL (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon resistant chronic hepatitis C. Gastroenterology107: 812–817.
14.
BrookMGChanGYapIKarayiannisPLeverAMJacynaMMainJ & ThomasHC (1989) Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. British Medical Journal299: 652–656.
15.
BruggerSAOesterreicherCHofmannJKalhsPGreinixHT & MullerC (1997) Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor. Lancet349: 996–997.
16.
BrunettoMROliveriFColombattoPCapalboMBarberaC & BoninoF (1995) Treatment of chronic anti-HBe positive hepatitis B with interferon alpha. Journal of Hepatology22(Suppl. 1): 42–44.
17.
CampsJGarciaNRiezu-BojJICiveiraMP & PrietoJ (1993) Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. Journal of Hepatology19: 408–412.
18.
CarmanWFJacynaMRHadziyannisS & KarayiannisPMcGarveyMJMakrisA & ThomasHC (1989) Mutation preventing formation of hepatitis HB e antigen in chronic hepatitis B virus infection. Lancetii: 588–591.
19.
CarrenoV & QuirogaJA (1997) Biological properties of inter-leukin-12 and its therapeutic use in persistent hepatitis B and hepatitis C virus infection. Journal of Viral Hepatitis4: 11419–1425.
20.
ChangMHChenCJLaiMSHsuHMWuTCKongMSLiangDCShauWY & ChenDS (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New England Journal of Medicine336: 1855–1859.
21.
ChemelloLAlbertiARoseK & SimmondsP (1994a) Hepatitis C serotype and response to interferon therapy. New England Journal of Medicine330: 143.
22.
ChemelloLCavalettoLBernardinelloESilvestriEBenvegnuLPontissoP & AlbertiA (1994b) Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes. Journal of Hepatology (supplement 1) 21: S12.
23.
ChemelloLCavallettoLBernardinelloEGuidoMPontissoP & AlbertiA (1995) The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. Journal of Hepatology23: 8–12
24.
ChemelloLCavalettoLDonadaCBonettiPCasariP & UrbanF (1997) Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology113: 1654–1659.
25.
ChooQ-LKuoGWeinerAJOverbyLRBradleyDW & HoughtonM (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science244: 359–62.
26.
ColledgeDLocarniniS & ShawT (1997) Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penci-clovir. Hepatology26: 216–225.
27.
ColucciG & GitekunstK (1997) Development of quantitative PCR assay for monitoring HCV viraemia levels in patients with chronic hepatitis C. Journal of Viral Hepatology4: 75–78.
28.
DavisGL (1994) Prediction of response to interferon treatment of chronic hepatitis C. Journal of Hepatology21: 1–3.
29.
DavisGLBalartLA & SchiffER (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. New England Journal of Medicine321: 1501–1506.
30.
Di BisceglieAMMartinPKassianidesCLisker-MelmanMMurrayLWaggonerJGoodmanZBanksSM & HoofnagleJH (1989) Recombinant interferon alfa therapy for chronic hepatitis C: A randomized double blind placebo-controlled trial. New England Journal of Medicine321: 1506–1510.
31.
Di BisceglieAMShindoMFongT-LFriedMWSwainMGBergasaNVAxiotisCAWaggonerJGParkY & HoofnagleJH (1992) A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology16: 649–654.
32.
Di BisceglieAMBaconBRKleinerDE & HoofnagleJH (1994) Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. Journal of Hepatolology21: 1109–1112.
33.
Di BisceglieAMConjeevaramHSFriedMWSallieRParkY & YurdaydinC (1995) Ribavirin as therapy for chronic hepatitis C. Annals of Internal Medicine123: 897–903.
34.
DienstagJLPerrilloRPSchiffERBartholomewMVicaryC & RubinM (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. New England Journal of Medicine333: 1657–1661.
35.
DuflotAMehrotraRYuSZBarraudLTrepoC & CovaL (1995) Spectrum of liver disease and duck hepatitis B virus infection in a large series of Chinese ducks with hepatocellular carcinoma. Hepatology21: 1483–1491
36.
EnomotoNSakumaIYAKuorsakiMMurakamiTYamamotoCIzumiNMarumoF & SatoC (1995) Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Journal of Clinical Investigation96: 224–230.
37.
EronJJBenoitSLJemsekJMacArthurRDSantanaJQuinnJBKuritzkesDRFallonMA & RubinM (1995) Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New England Journal of Medicine333: 1662–1669.
38.
FargionSFracanzaniALSampietroMMolteniVBoloriniR & MattioliM (1997) Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. European Journal of Gastroenterology and Hepatology9: 4497–503.
39.
FattovichGGiustinaGAlbertiAGuidoMPontissoPFavaratoSBenvegnuL & RuolA (1994) A randomised controlled trial of thymopentin therapy in patients with chronic hepatitis B. Journal of Hepatology21: 361–366.
40.
FattovichGGiustinaGRealdiGCorrocherR & SchalmSW (1997) European concerted action on viral hepatitis. Long term outcome of hepatitis B e antigen positive patients with compensated cirrhosis treated with interferon alfa. Hepatology26: 1338–1342.
41.
FerayCGigouMSamuelDParadisVMishiroSMaertensGReynesMOkamotoHBismuthH & BrechotC (1995) Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology108: 1088–1096.
42.
FosterGRGoldinRDMainJMurray-LyonIHargreavesS & ThomasHC (1997) Management of chronic viral hepatitis C; clinical audit of biopsy based management algorithm. British Medical Journal315: 453–458
43.
FosterGRGoldinRD & ThomasHC (1998) Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology27: 209–212
44.
GarciaGSmithCIWeissbergJIEisenbergMBissettJNairPVMastreBRosnoSRoskampDWatermanKPollardRBTongMJBrownBWRobinsonWSGregoryPB & MeriganTC (1987) Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. Annals of Internal Medicine107: 278–285.
45.
GavierBMartinez-GonzalezMARiezu-BpjJILasarteJJGarciaNCiveiraMP & PrietoJ (1997) Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology113: 1647–1653.
46.
GreenbergHBPollardRBLutwickLIGregoryPBRobinsonWS & MeriganTC (1976) Effect of human leucocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. New England Journal of Medicine295: 517–522.
47.
HadlerSCJudsonFNO'MalleyPMAltmanNLPenleyKBuchbinderSSchableCAColemanPJOstrowDN & FrancisDP (1991) Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. Journal of Infectious Diseases163: 454–459.
48.
HadziyannisSBramouTMakrisAMoussoulisGZignegoL & PapaioannouC (1990) Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. Journal of Hepatology11: S133–136.
49.
HayashiJKishiharaTUenoKYamajiKKawakamiY & FurusyoN (1998) Age-related response to inteferon alfa in women vs men with chronic hepatitis C virus infection. Archives of Internal Medicine158: 177–181.
50.
HeijtinkRAKruiningJHonkoopPKuhnsMCHopWCJOsterhausADME & SchalmSW (1997) Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B. Journal of Medical Virology53: 282–287.
51.
HinoKOkudaMKonishiTIchikoH & OkitaK (1995) Serial assay of hepatitis C virus RNA in serum for predicting response to interferon alpha therapy. Digestive Disease Sciences40: 14–20.
52.
HofgartnerWTPolyakSJSullivanDGCairthersRL & GretchDR (1997) Mutations in the NS5A gene of hepatitis C virus in North American patients infected with hepatitis C genotype 1a or 1b. Journal of Medical Virology53: 118–126.
53.
HonkoopPDemanRAScholteHRZondervanPEvan den BergJWORademakersLHPM & SchalmSW (1997a) Effect of lamivudine on morphology and function of mitcohondria in patients with chronic hepatitis B. Hepatology26: 211–215.
54.
HonkoopPNiestersHGMde ManRAMOsterhausADME & SchalmSW (1997b) Lamivudine resistance in immunocompetent chronic hepatitis B — Incidence and patterns. Journal of Hepatology26: 1393–1395.
55.
HoofnagleJHMullenKDJonesDBRustgiVDi BisceglieAPetersMWaggonerJGParkY & JonesEA (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. New England Journal of Medicine315: 1575–1578.
56.
IdeTSataMSuzukiHUchimuraYShirachiMAdachiN & TanikawaK (1997) Characterisitics of complete responders to interferon among patients with chronic hepatitis C with high serum levels of RNA. Hepatology Research7: 19–27.
57.
International Interferon-α Hepatocellular Carcinoma Study Group. (1998). Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet351: 1535–1539.
58.
JacynaMRBrooksMGLokeRHTMainJMurray-LyonIM & ThomasHC (1989) Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. British Medical Journal298: 80–82.
59.
JohnsonRJGretchDRYamabeHHartJBacchiCEHartwellPCouserWGCoreyLWenerMHAlpersCE (1993). Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. New England Journal of Medicine328: 465–470.
60.
JouetPRoudot-ThorvalFDhumeauxDMetreauJ-M et Le Groupe Francais pour l'etude du traitement des hepatites chroniques NANB/C (1994) Comparative efficacy of interferon alfa in cirrhotic and non-cirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology106: 686–690.
61.
KanaiKKatoM & OkamatoH (1992) HCV genotypes in chronic hepatitis C and response to interferon. Lancet339: 1543.
62.
KimWRPoteruchaJJHermansJETherneauTMDicksonEREvansRW & GrossJB (1997) Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Annals of Internal Medicine127: 866–874.
63.
KorenmanJBakerBWaggonerJEverhartJEDi BisceglieAM & HoofnagleJH (1991) Long term remissions of chronic hepatitis B after alpha interferon. Annals of Internal Medicine114: 629–634.
64.
LaiCLLokASFLinHJ (1987) Placebo-controlled trial of recombinant alfa2 interferon (rIFN) in Chinese HBsAg carrier children. Lancetii: 877–880.
65.
LaiM-YKaoJ-HYangP-MWangJ-TChenP-J & ChanK-W (1996) Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology111: 1307–1312.
66.
LaiC-LLiawY-FLeungNDeslauriersMBarnardJSanthananL (1997) Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: Incidence, kinetics of emergence and correlation with disease parameters. Hepatology26: 522.
67.
LaiC-LChienR-NLeungNChangT-TGuanRTaiD-INgK-YWuP-CDentJCBarberJStephensonSL & GrayDF (1998) A one year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine339: 61–68.
68.
LamperticoPdel NonnoEManzinADonatoMFRumiMG & LunghiG (1997) A randomised controlled trial of a 24 month course of interferon afa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology26: 1621–1625.
69.
LauDTEverhartJKleinerDEParkYVergallaJSchmidP & HoofnagleJH (1997a) Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology113: 1660–1667.
70.
LauGKKLokASFLiangRHSLaiCLChiuEKW & LauYL (1997b) Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immmunity transfer. Hepatology25: 1497–1501.
71.
LeeCL & KoYC (1997) Hepatitis B vaccinarion and hepatocellular carcinoma in Taiwan. Pediatrics99: 351–353.
72.
LeeJ-Hvon WagnerMRothWKTeuberGSarrazinC & ZeuzemS (1998) Effect in ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. Journal of Hepatology29: 29–35.
73.
LingRMutimerDAhmedMBoxallEHEliasEDusheikoG & HarrisonTJ (1996) Selection of mutations in the hepatitis B virus polymerase during treatment of transplant recipients with lamivudine. Hepatology24: 711–713.
74.
MainJBrownJLHowellsCGalassiniRCrosseyMKarayiannisPGeorgiouPAtkinsonG & ThomasHC (1996) A double blind placebo-controlled study to assess the effect of famciclovir in virus replication in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis3: 211–215.
75.
MarcellinPGiuilyNLoriotMADurandFSamuelD & BettanL (1997) Prolonged interferon-alpha therapy of hepatitis B virus related decompensated cirrhosis. Viral Hepatitis4: 21–26.
76.
McKenzieRFriedMWSallieRConjeevaramHDi BisceglieAMParkYSavareseBKleinerDTsokosMLucianoCPruettTStotkaJLStrausSE & HoofnagleJH (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine333: 1099–1105.
77.
MarcellinPPouteauMMartinot-PeignouxMDegosFDuchatelleVBoyerNLemonnierCDegottCErlingerS & BenhamouJP (1995) Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology109: 156–165.
78.
MilellaMAntonelliGSantantonioTCurrentiMMonnoLMarianoNAngaranoGDianzaniF & PastoreG (1993) Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver13: 146–150.
79.
NevensFMainJHonkoopPTyrrellDLBarberJ & SullivanMT (1997) Lamivudine therapy for chronic hepatitis B; a six month randomised dose-ranging study. Gastroenterology113: 1258–1263.
80.
NiederauCHeintgesTLangeSGoldmanGNiederauCMMohrL & HaussingerD (1996) Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B. New England Journal of Medicine334: 1422–1427.
81.
NIH Consensus Group (1997) National Institute of Health consensus development conference panel statement: Management of hepatitis C. Hepatology26 (Suppl. 1): 2S–10S.
82.
NishiguchiSKurokiTNakataniSMorimotoHTakedaTNakajimaSShiomiSSekiSKobayashiK & OtaniS (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet346: 1051–1055
83.
NowakMABonhoefferSHillAMBoehmeRThomasHC & McDadeH (1996) Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences, USA93: 4398–4402.
84.
OlanoJPBoruckiMJWenJW & HaqueAK (1995) Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clinical Infectious Diseases21: 973–976.
85.
PennaAdel PreteGCavalliABertolettiAD'EliosMM & SorrentinoR (1997) Predominant T-helper cytokine profile of hepatitis B virus nucleocapsid-specific T cellls in acute self-limited hepatitis B. Hepatology25: 1022–1027.
86.
PerrilloRRegensteinFBodickyCCampbellCJ & SunwooYC (1985) Comparative efficacy of adenine arabinoside 5′-monophosphate and prednisone withdrawal followed by adenine arabinoside 5′-monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology88: 780–786.
87.
PerrilloRPSchiffERDavisGLBodenheimerHCLindsayKPayneJDienstagJLO'BrienCTamburroCJacobsonIMSamplinerRFeitDLefkowitchJLKuhnsMMeschievitzCSanghviBAlbrechtJ & GibasA (1990) A randomised controlled trial of interferon alfa 2-b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. New England Journal of Medicine323: 295–301.
88.
PoynardTBedossaPChevallierMMathurinPLemonnierCTrepoCCouzigouPPayenJLSajusMCostaJMVidaudM & ChaputJC (1995) A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. New England Journal of Medicine332: 1457–1462.
89.
Protzer-KolleUNaumannUBartenschlagerRBergTHopfU & zum BuschenfeldeMeyer KH (1998) Hepatitis B virus with anti-genically altered hepatitis B surface antigen is selected by high dose hepatitis B immune globulin after liver transplantation. Hepatology27: 254–263.
90.
ReichardOAnderssonJSchvarczR & WeilandO (1991). Ribavirin treatment for chronic hepatitis C. Lancet337: 1058–1061.
91.
ReichardOFobergUFrydenAMattsonLNorkransGSonnerborgAWejstalRYunZ-B & WeilandO (1994) High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-a2b for 60 weeks. Hepatology19: 280–285.
92.
ReichardONorkransGFrydenABraconierJHSonnerborgA & WeilandO (1998) Randomised, double-blind, placebo-controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. Lancet352: 83–87.
93.
RollinoCRoccatelloDGiachinoOBasoloB & PiccoliG (1991) Hepatitis C virus infection and membranous glomerulonephritis. Nephron59: 319–320.
94.
SamuelDMullerRAlexanderGFassatiLDucotBBenhamouJ-P & BismuthH (1993) Liver transplantation in European patients with the hepatitis B surface antigen. New England Journal of Medicine329: 1842–1847.
95.
SangiovanniAMoralesRSpinziGRumiMCasraghiA & CerianiR (1998) Interferon alpha treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomised controlled trial. Hepatology27: 853–856.
96.
ScullardGHPollardRBSmithJLSacksSLGregoryPBRobinsonWS & MeriganTC (1981) Antiviral treatment of chronic hepatitis B virus infection. Changes in viral markers with interferon combined with adenine arabinoside. Journal of Infectious Diseases143: 772–783.
97.
SellsMAChenM & AcsG (1987) Production of hepatitis B virus particles in hepG2 cells transfected with cloned hepatitis B virus DNA. Proceedings of the National Academy of Sciences, USA84: 1005–1009.
98.
SeveriniALiuX-YWilsonJ & TyrrellD (1995) Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′, 3′ dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy39: 1430–1435.
99.
SinghNGayowskiTWannstedtCFWagenerCFWagenerMM & MarinoIR (1997) Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation63: 1415–1419.
100.
SmithJP (1997) Treatment of chronic hepatitis C with amantadine. Digestive Disease Sciences42: 121–129.
101.
SquadritoGLeoneFSartoriMNalpasBBerthelotP & RaimondoG (1997) Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C virus to interferon alfa. Gastroenterology113: 567–572.
102.
SummersJSmolecJMSnyderR (1978) A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in wood-chucks. Proceedings of the National Academy of Sciences, USA75: 4533–4537
103.
TennantBC & GerinGL (1994) The woodchuck model of hepatitis B virus infection. In The Liver: Biology and Pathobiology, pp. 1455–1466. New York: Raven Press.
104.
ThurszMKwiatowskiDAllsoppCEGreenwoodBM & ThomasHC (1995) Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. New England Journal of Medicine332: 1065–1069.
105.
TongMJBlattLMMcHutchisonJGCoRL & ConradA (1997) Prediction of response during interferon alfa 2b therapy in chronic hepatitic C using viral and biochemical characteristics: A comparison. Hepatology26: 1640–1645.
106.
TrepoCHantzOOuzanDFontagnesT (1984) Therapeutic efficacy of adenine arabinoside monophosphate in symptomatic HBeAg positive chronic active hepatitis: A randomised placebo controlled study. Hepatology4: 1055–1061.
107.
TrepoCJezekPAtkinsonGF & BoonRJ on behalf of the FCV chronic hepatitis B study group. (1997) Long term efficacy of famciclovir (FCV) in chronic hepatitis B: Results of a phase IIB study. Journal of Hepatology26 (Suppl. 1): Abstract WP3/22.
108.
TsaiNCSZuckermanEHanSHGoadKRedekerAG & FongTL (1997) Effect of iron depletion on long-term response to interferon-alpha therapy in patients with chronic hepatitis C who previously did not respond to interferon therapy. American Journal of Gastroenterology92: 1831–1834.
109.
TyrrellDLJMitchellMCDe ManRASchalmSWMainJThomasHCFeveryJNevensFBeranekP & VicaryC (1993) Phase II trial of lamivudine for chronic hepatitis B. Hepatology (Suppl.) 18: 112A.
110.
YoshiokaKKakumuSWakitaTIshikawaTItohYTakayanagiMHigashiYShibataM & MorishimaT (1992). Detection of hepatitis C virus by polymerase chain reaction and response to interferon alpha therapy: Relationship to genotypes of hepatitis C virus. Hepatology16: 293–299.
